ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / UNCY / forecast
ORGO (34) VTVT (24) IMUX (33) NRXP (25) ⌘ Pro Terminal →

Unicycive Therapeutics Inc. (UNCY) 12-Month Stock Forecast & Price Target Cone

$3.49 -6.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.44

Unicycive Therapeutics Inc. (UNCY) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $97.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UNCY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UNCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Unicycive Therapeutics Inc. (NASDAQ: UNCY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.49 (-6.68% 1D, market cap $97.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, UNCY ranks #764 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UNCY compare to ORGO and VTVT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UNCY carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ORGO (Organogenesis Holdings Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $97.2M) and VTVT (vTv Therapeutics Inc. (Class A)) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $95.5M). Among the 5-stock peer group, UNCY leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UNCY?
▼

Per UNCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001766140), Unicycive Therapeutics Inc. generated $82.6M in revenue (-8.1% YoY), -$26.6M in net income, and -$31.3M in free cash flow against $49.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.44 (-1.39%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (4)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12% Base Target
$9 Bull$3 Base$2 Bear
📬 FREE UNCY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UNCY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY UNCY SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (29% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 34.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$3.73+1.9% Next Q
Q2 (-2Q)
36
Grade E$3.80-5% Next Q
Q3 (-1Q)
34
Grade E$3.61-3.3% Next Q
Current
31
Grade E$3.49-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a UNCY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While UNCY currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.46) and Max Pain ($3.66) forces dealer call-delta covering toward $9.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UNCY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “UNCY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your UNCY Position Size: $10,000

Shares at $3.49: 2865.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.39
$6,848
$-3,152 (-31.5%)
12M Consensus BaseTarget $3.07
$8,797
$-1,203 (-12.0%)
12M Bull Case BreakoutTarget $9.18
$26,304
+$16,304 (+163.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$374%A
Goldman SachsSector Coverage LeadUNDERPERFORM$969%B
JP MorganUS Large-Cap ResearchSELL$358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring UNCY)

  • ✓Walkthrough of UNCY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
UNCY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.81%⚡ TESTING RESISTANCE
2026-11-04O $3.74H $3.74L $3.49C $3.49VOL 2.24M
RES: $3.70SUP: $3.06SMA50: $4.46SMA200: $6.08
$9.12$7.55$5.99$4.43$2.86RES $3.70SUP $3.06$3.492026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UNCY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UNCY Butterfly Map → + Track UNCY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on UNCY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UNCY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for UNCY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UNCY)

Health Care Rank #764 of 1015 ⚔️ ORGO vs UNCY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UNCY vs. ORGO, VTVT, IMUX, NRXP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Unicycive Therapeutics Inc. (UNCY) ranks #764 by composite RQD confidence (31/100, grade E) and #652 by equity capitalization ($97.2M). Within this direct 5-issuer industry benchmark cohort, UNCY leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with UNCY at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
UNCY ACTIVE
Unicycive Therapeutics Inc.
E 31/100 — — -35.0% -6.68% $97.2M Benchmark Subject
ORGO
Organogenesis Holdings Inc. (Class A)
E 34/100 — — 17.1% -1.64% $97.2M /orgo-vs-uncy →
VTVT
vTv Therapeutics Inc. (Class A)
E 24/100 — — -35.0% -4.05% $95.5M /vtvt-vs-uncy →
IMUX
Immunic Inc.
E 33/100 — — -35.0% -2.26% $100.2M /imux-vs-uncy →
NRXP
NRX Pharmaceuticals Inc.
E 25/100 — 58.8% -35.0% -4.40% $94.0M /nrxp-vs-uncy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001766140 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Unicycive Therapeutics Inc. (UNCY) reported GAAP revenue of $82.6M (-8.1% vs. FY2024 revenue of $89.9M , and +12144.1% cumulative change since FY2023) , GAAP net income of -$26.6M, operating cash flow of -$31.3M, and free cash flow of -$31.3M (-9.4% YoY). On the balance sheet, UNCY closed FY2025 with $49.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $82.6M -$26.6M -$31.3M -$31.3M $49.1M —
FY2024 (FY) 2024-12-31 $89.9M -$36.7M -$28.6M -$28.6M $31.7M —
FY2023 (FY) 2023-12-31 $675.0K -$30.5M -$18.3M -$18.3M — —

3. UNCY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UNCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Unicycive Therapeutics Inc. (NASDAQ: UNCY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.49 (-6.68% 1D, market cap $97.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, UNCY ranks #764 in composite RQD confidence.

How does UNCY compare to ORGO and VTVT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UNCY carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ORGO (Organogenesis Holdings Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $97.2M) and VTVT (vTv Therapeutics Inc. (Class A)) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $95.5M). Among the 5-stock peer group, UNCY leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for UNCY?

Per UNCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001766140), Unicycive Therapeutics Inc. generated $82.6M in revenue (-8.1% YoY), -$26.6M in net income, and -$31.3M in free cash flow against $49.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is UNCY trading relative to its 50-day, 200-day, and 52-week technical levels?

UNCY last traded at $3.49 (-6.68% on volume of 2,235,121 shares), positioning the stock -21.75% below its 50-day simple moving average ($4.46) and -42.60% below its 200-day simple moving average ($6.08). Across its 52-week range of $3.35 to $8.74, UNCY sits at the 2.6% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.05 to $3.93).

Direct Sub-Reports: UNCY RQD Cockpit UNCY 12M Forecast UNCY Earnings & Move UNCY Dividends & DRIP UNCY Insiders & 13F UNCY Whale Options UNCY Profit Sankey UNCY News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

UNCY — Unicycive Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Unicycive Therapeutics Inc. (UNCY) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.49 (-6.68% 1D, market capitalization $97.2M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Unicycive Therapeutics Inc. (UNCY) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.1B. Revenue is reported as — in FY 2025 and FY 2024 (), indicating no meaningful commercial revenue in those periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Unicycive Therapeutics Inc. (UNCY) reported $82.6M in annual revenue (up from $89.9M in FY2024, -8.1% YoY) and -$26.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($675.0K revenue, -$30.5M net income) through FY2025, UNCY scaled operating cash flow to -$31.3M and free cash flow to -$31.3M, backed by $49.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.35 – $8.74 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided sources. The only sector context available is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification.

  • Key Question #1: Can UNCY sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $82.6M and free cash flow of -$31.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is UNCY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

UNCY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Unicycive Therapeutics Inc. (UNCY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UNCY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UNCY Bull vs. Bear Conversation Board — What's Your Call at $3.49?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UNCY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on UNCY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $4.68 (+25.1%)
📌 Pinned Debate

Balance sheet pillar scores 10/20 with Altman Z 2.5 and Debt/Equity 0.5, and cash of $29.2M is reported at FY 2025, so leverage is not

Don't sleep on UNCY's setup in Health Care. Balance sheet pillar scores 10/20 with Altman Z 2.5 and Debt/Equity 0.5, and cash of $29.2M is reported at FY 2025, so leverage is not the primary weakness.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — UNCY's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.18 (-15.0%)
Spot @ $3.74

Fundamental Cash Engine scores 4/20 with ROIC of -35% and FCF yield of 0%, while FY 2025 free cash flow was -$31.3M against a $106.1M m

Sitting on the sidelines or leaning short UNCY above $3.74. Fundamental Cash Engine scores 4/20 with ROIC of -35% and FCF yield of 0%, while FY 2025 free cash flow was -$31.3M against a $106.1M market capitalization.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $8.74.

LIVE TAPE